Zentiva, Insud Pharma and an originator drug company explain
how large molecule market dynamics have shifted the litigation format created
by small molecule products, turning other generics and innovators into
litigation targets. (Read
more … )
In-house counsel explain what they’ve done so far to prepare
for the Unified Patent Court, but say they’re unlikely to increase
preparations, despite the complaint holding up the system’s creation being
moved to this year’s agenda. (Read more … )
Patent departments say financial constraints have compelled more businesses to abandon or sell off less valuable registrations – but they add that they are careful not to get rid of the wrong ones. (Read more … )
Sign up to receive more content like this in Patent Strategy’s weekly newsletter.
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.